Essence Pharmaceutical (002349.SZ): Salfamide mesylate obtained approval for marketing application as a chemical raw material

Zhitong Finance App News, Jinghua Pharmaceutical (002349.SZ) issued an announcement. Recently, the company Sun Jinghua Pharmaceutical Group Nantong Co., Ltd. (hereinafter referred to as “Nantong Company”) obtained the approval and issuance of the “Notice of Approval of the Marketing Application for Chemical Ingredients” for salfiamide mesylate from the State Drug Administration.

Salfamide mesylate is an anti-Parkinson's raw material and is mainly used to treat Parkinson's disease. The approval of this API indicates that Nantong Company is eligible for the domestic marketing and supply of the API for salfiamide mesylate. The registration status of the API was simultaneously changed to “A”, and it can be supplied to domestic pharmaceutical companies for formulation declaration and production use.

This time, salfiamide mesylate obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients”, which further enriches the company's API product pipeline and improves the company's product layout, which is conducive to enhancing the company's market competitiveness in the field of specialty APIs and has a positive impact on the company's future business development.